Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as...
Haleos Labs reported revenue of 3.37 billion INR for fiscal year 2025, up 12.4% from fiscal year 2024, and net income of 201.09 million INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 825.05 million INR, down 10.9% from a year before. India was its largest region in fiscal year 2025, with 58% of revenue. Its market capitalization was 4.16 billion INR as of November 25, 2025.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of November 25, 2025.
No profile data available.